Drug intelligence / Profile preview

APP-309

Development stage: Preclinical
Lead developer: Aphios
Modality: Small Molecules

Overview

APP-309 is a marine microorganism-derived small molecule being developed by Aphios Pharma for the treatment of influenza. Discovered through a screening program of marine-derived compounds, APP-309 has demonstrated anti-influenza activity in preclinical research. The program is currently in the research lead stage, with the specific molecular target and mechanism of action yet to be publicly characterized.

Targets

Flu (Influenza surface proteins)

Beyond the preview

Go deeper on APP-309.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APP-309.

Explore the full profile